Patents Examined by Kay K. Kim
  • Patent number: 5756104
    Abstract: The present invention relates to a vaccine formulation for intranasal or inhalation administration, and to the preparation thereof, which formulation contains antigenic material freely mixed with empty liposomes.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: May 26, 1998
    Assignee: Duphar International Research B.V.
    Inventors: Aalzen de Haan, Harmen J. Geerligs, Jan C. Wilschut
  • Patent number: 5681927
    Abstract: Chelated radionuclide compositions are provided for conjugation to polypeptides and carbohydrates. The resulting conjugates may be used in diagnosis and therapy.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: October 28, 1997
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Sudhakar Kasina, Tripuraneni N. Rao, Jean-Luc VanderHeyden, Ananthachari Srinivasan
  • Patent number: 5672687
    Abstract: The invention relates to magnetic protein conjugates of the formula I ##STR1## in which M represents a dispersible magnetically reacting material or particle which carries aminogroups, Ig represents a protein which carries one or more mercapto groups, and X represents an organic chemical structure which links the two ligands by chemical means, to a process for the preparation of protein conjugates of the formula I, and to the use of conjugates of this type for removing cells or soluble bioorganic molecules or components from aqueous salt solutions or body fluids, and to the use thereof within the framework of a diagnostic method or as a diagnostic aid.
    Type: Grant
    Filed: January 19, 1995
    Date of Patent: September 30, 1997
    Assignee: Behringwerke Aktiengesellschaft
    Inventors: Peter Hermentin, Reiner Donges, Karlheinz Enssle, Roland Kurrle, Friedrich Robert Seiler
  • Patent number: 5623057
    Abstract: A novel conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process. The conjugate is useful in the prevention of pneumococcal infections. Vaccines comprising a mixture of from one to ten different pneumococcal polysaccharide-immunogenic protein (Pn-Ps-PRO) conjugates induce broadly protective recipient immune responses against the cognate pathogens from which the polysaccharide components are derived. Young children and infants younger than 2 years old, normally unable to mount a protective immune response to the Pn-Ps alone, exhibit protective immune responses upon vaccination with these Pn-Ps-PRO conjugates.
    Type: Grant
    Filed: May 20, 1994
    Date of Patent: April 22, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Stephen Marburg, Richard L. Tolman, Peter J. Kniskern, William J. Miller, Arpi Hagopian, Charlotte C. Ip, John P. Hennessey, Jr., Dennis J. Kubek, Pamela D. Burke
  • Patent number: 5616327
    Abstract: Peptides substantially corresponding to the 148-162 region of type A influenza M protein and additionally containing at least one amino acid in the 163-166 region are disclosed to have high activity as influenza transcription inhibitors and thus as antiviral agents against influenza virus and other RNA viruses. The modification of these peptides by incorporation into liposomes or by addition of long-chain alkylamino acids is also shown as in the use of all such materials in antiviral drug formulations.
    Type: Grant
    Filed: November 7, 1994
    Date of Patent: April 1, 1997
    Assignees: SRI International, New York Medical College
    Inventors: Amrit K. Judd, Doris J. Bucher
  • Patent number: 5616692
    Abstract: Chelated radionuclide compositions are provided for conjugation to polypeptides and carbohydrates. The resulting conjugates may be used in diagnosis and therapy.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: April 1, 1997
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Sudhakar Kasina, Tripuraneni N. Rao, Jean-Luc VanderHeyden, Ananthachari Srinivasan
  • Patent number: 5610283
    Abstract: The present invention is directed to novel opiate derivatives which are synthesized for the covalent attachment to antigens (proteins or polypeptides) for the preparation of antibodies or receptors to the opiates and opiate metabolites. The resulting novel antigens may be used for the production of antibodies or receptors using standard methods. Once generated, the antibodies or receptors and the novel derivatives which are covalently attached to proteins, polypeptides or labels may be used in the immunoassay process.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: March 11, 1997
    Assignee: Biosite Diagnostics Incorporated
    Inventor: Kenneth F. Buechler
  • Patent number: 5606028
    Abstract: Anchimeric chelates are disclosed which are capable of rapidly forming stable chelates with radionuclide metals at or below physiological temperature. Bifunctional anchimeric chelates having these same properties are also disclosed which are useful for radiolabeling target specific molecules such as monoclonal antibodies and fragments thereof.
    Type: Grant
    Filed: September 21, 1995
    Date of Patent: February 25, 1997
    Assignee: NeoRx Corporation
    Inventors: Alan R. Fritzberg, Ananthachari Srinivasan
  • Patent number: 5606030
    Abstract: A novel coconjugate comprising an immunogenic protein or protein complex having a first set of covalent linkages to low molecular weight moieties, --a.sup.--, which have an anionic or polyanionic character at physiological pH, and a second set of covalent linkages to peptides comprising Human Immunodeficiency Virus (HIV) Principal Neutralizing Determinants (PNDs), or peptides immunologically equivalent therewith, is useful for inducing anti-peptide immune responses in mammals, for inducing HIV-neutralizing antibodies in mammals, for formulating vaccines to prevent HIV infection or disease, including the Acquired Immune Deficiency Syndrome (AIDS), or for treating humans afflicted with HIV infection or disease.
    Type: Grant
    Filed: September 14, 1994
    Date of Patent: February 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Emilio A. Emini, William J. Leanza, Stephen Marburg, Richard L. Tolman
  • Patent number: 5602005
    Abstract: A substantially purified intra-acrosomal primate sperm antigen useful in a contraceptive vaccine is disclosed herein. The antigen remains associated with primate sperm after the acrosome reaction. In particular, it remains associated with the inner and outer acrosomal membranes. Modified antigens and fragments thereof prepared by protein modification techniques are also disclosed as well as methods for purifying and using the antigens. Also disclosed are monoclonal and polyclonal antibodies to the antigen and methods of making and using such antibodies. Methods of use include purification of the antigen or use in various diagnostic techniques. Also disclosed are cDNA, expression vectors, and transformed microorganisms that produce the antigen.
    Type: Grant
    Filed: August 18, 1994
    Date of Patent: February 11, 1997
    Assignee: The University of Virginia Alumni Patents Foundation
    Inventors: John C. Herr, Richard M. Wright
  • Patent number: 5597573
    Abstract: The present invention relates to novel amidine components of formula (II): ##STR1## A method for eliciting antibodies in an animal which bind to Lipid A or LPS comprising administering to the animal as an immunogen a composition comprising such a compound is also disclosed.
    Type: Grant
    Filed: March 14, 1995
    Date of Patent: January 28, 1997
    Assignee: Igen, Inc.
    Inventors: Balreddy Kamireddy, Michael J. Darsley, David M. Simpson, Richard J. Massey
  • Patent number: 5593897
    Abstract: A method of binding aggregated immunoglobulin or immune complexes comprising contacting them with modified forms of C-reactive protein. The method may be employed for diagnostic and therapeutic purposes and to deplete fluids of aggregated immunoglobulin or immune complexes. Further, a method of reducing the levels of immune complexes in a mammal comprising administering modified-CRP to the mammal, and a method of binding immunoglobulins comprising contacting them with modified C-reactive protein. Also, a method of binding aggregated immunoglobulin or immune complexes comprising contacting them with antibody to neo-CRP, and a method of modifying C-reactive protein. Finally, a test kit for detecting or quantitating immune complexes and a device for removing aggregated immunoglobulin or immune complexes from fluids are disclosed.
    Type: Grant
    Filed: July 6, 1994
    Date of Patent: January 14, 1997
    Assignee: Northwestern University
    Inventors: Lawrence A. Potempa, Byron E. Anderson
  • Patent number: 5583031
    Abstract: The invention features an isolated sample of mammalian class II major histocompatibility heterodimers which are membrane-associated or in soluble form, and which are capable of binding added antigenic peptide; methods for producing large amounts of the soluble or membrane-associated histocompatibility protein by expression of DNA encoding the .alpha. and .beta. polypeptides; and methods for loading these heterodimers with any desired antigen.
    Type: Grant
    Filed: February 6, 1992
    Date of Patent: December 10, 1996
    Assignee: President and Fellows of Harvard College
    Inventor: Lawrence J. Stern
  • Patent number: 5583000
    Abstract: Non-peptide, protease-binding compounds are described as useful in the detection, labelling, and inhibition of retroviral proteases. Aryl piperidinyl derivatives and other compounds related in structure have been found to be HIV-1 and HIV-2 protease-binding compounds.
    Type: Grant
    Filed: September 16, 1993
    Date of Patent: December 10, 1996
    Assignee: The Regents of the University of California
    Inventors: Paul R. Ortiz de Montellano, Irwin D. Kuntz, Charles S. Craik, Paul S. Furth, Juan C. Alvarez, Patricia S. Caldera, Dianne L. DeCamp, Lilia M. Bab e, James De Voss, Rafael Salto, Zhihua Sui
  • Patent number: 5580563
    Abstract: A multiple antigenic peptide system is disclosed that comprises a dendritic core and peptide and a lipophilic anchoring moiety. This particular combination has as an advantage that it eliminates the need for the inclusion of adjuvants found to be toxic to humans, and facilitates the exponential amplification of the antigenic potential of a vaccine prepared therefrom, as noncovalent amplification by a liposome or micellar form is possible. Further, multiple different antigenic peptides may be attached so that the system may be prepared for administration to concurrently treat diverse ailments, such as for example, AIDS and influenza. The present multiple antigen peptide system is capable of eliciting an immune response when injected into a mammal, and accordingly, vaccines prepared from the system and methods of use including therapeutic protocols are included.
    Type: Grant
    Filed: December 28, 1994
    Date of Patent: December 3, 1996
    Inventor: James P. Tam
  • Patent number: 5578308
    Abstract: A detoxified B. pertussis toxin or antigenic preparation is described, which is characterized by stability to reversion to toxicity upon storage at C. and at temperatures above C. Also provided are methods for producing detoxified pertussis toxin and vaccines containing same.
    Type: Grant
    Filed: November 14, 1994
    Date of Patent: November 26, 1996
    Inventors: Carine Capiau, Jean Petre
  • Patent number: 5578482
    Abstract: The present invention relates to erbB-2 ligands and functional derivatives thereof which are capable of binding to the erbB-2 oncogene product. The present invention further pertains to anti-ligand molecules capable of recognizing and binding to the erbB-2 ligand molecule and to screening assays for such ligands. The present invention additionally relates to uses for the erbB-2 ligand, the anti-ligand molecules and the screening assays.A method for inhibiting the growth of adenocarcinoma cells in a human, which cells overexpress the oncogene erbB-2, which entails administering to said human an amount of a 30 kDa glycoprotein effective to inhibit the growth of said cells.
    Type: Grant
    Filed: July 26, 1993
    Date of Patent: November 26, 1996
    Assignee: Georgetown University
    Inventors: Marc E. Lippman, Ruth Lupu
  • Patent number: 5576002
    Abstract: Neisseria meningitidis group B polysaccharide (GBMP) modified by having sialic acid residue N-acetyl groups replaced by N-acyl groups exhibits enhanced immuno response thereto. In addition, induction of antibodies which cross-react with unmodified group B meningococcal and E. coli K1 capsular polysaccharide and other tissue cells having a common epitope is minimized. Conjugation of the modified polysaccharides with a physiologically acceptable protein such as tetanus toxoid induces the production of specific protective antibodies with negligible levels of GBMP-cross reactive antibodies, to thereby afford protection against infections caused by group B meningococci and E. coli K1.
    Type: Grant
    Filed: May 5, 1994
    Date of Patent: November 19, 1996
    Assignee: National Research Council of Canada
    Inventors: Harold J. Jennings, Francis Michon
  • Patent number: 5573767
    Abstract: Method for improving the organoleptic qualities of the meat from uncastrated male domestic animals, vaccines which are usable in this method, new peptide, in particular, for producing these vaccines and vaccination kit relating thereto.The method for improving the organoleptic qualities, especially the smell, taste and tenderness, of the meat from uncastrated male domestic animals comprises, shortly before slaughter of the animal in question, abolition of the action of the androgenic and non-androgenic steroids by active or passive anti-LHRH immunoneutralization, while the advantages linked to the male character of the animal are maintained virtually up to slaughter. The vaccines comprise, as a peptide, natural LHRH or a peptide of formula Trp - Ser - Tyr - Gly - Leu - Arg - Pro - Gly - NH.sub.2, coupled to an immunogenic carrier protein.
    Type: Grant
    Filed: November 17, 1994
    Date of Patent: November 12, 1996
    Assignee: Societe Anonyme
    Inventors: Raymond Dufour, Claude Roulet, Claire Chouvet, Michel B. Bonneau
  • Patent number: RE35491
    Abstract: Methods and compositions for detecting the presence of tumors are provided, where a physiological sample is assayed for the expression product of a c-onc gene as diagnostic for the presence of the tumor. The method finds use in both pre-and postoperative situations with a host suspected of having transformed malignant cells.
    Type: Grant
    Filed: October 12, 1989
    Date of Patent: April 8, 1997
    Assignee: The Regents of the University of California
    Inventors: Martin J. Cline, Dennis J. Slamon